Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is a pioneering specialty pharmaceutical company dedicated to developing and commercializing next-generation, abuse-deterrent products aimed at treating chronic pain and other serious medical conditions. Leveraging its proprietary DETERx® technology platform, Collegium creates formulations designed to mitigate the risks associated with the misuse and abuse of prescription medications. The DETERx technology maintains the extended-release and safety profiles of commonly abused drugs, such as opioids and amphetamines, even when subjected to tampering methods like crushing, chewing, or dissolving.
Collegium's lead product, Xtampza ER™, is an extended-release, oral formulation of oxycodone that incorporates abuse-deterrent properties. The company's product portfolio also includes the Nucynta® Products (extended-release and immediate-release formulations of tapentadol), Belbuca® (buccal film for severe chronic pain), and Symproic® (for opioid-induced constipation).
In recent news, Collegium announced its financial results for the quarter ended September 30, 2023, reporting a solid financial performance and an optimistic outlook for 2025 and 2026. The company achieved record quarterly revenue for Belbuca and has initiated an Accelerated Share Repurchase (ASR) program, further demonstrating its commitment to returning value to shareholders. The extension of Nucynta's regulatory exclusivity through July 2026 has also strengthened the company's future market positioning.
Headquartered in Stoughton, Massachusetts, Collegium continues to focus on operational excellence and disciplined capital deployment to enhance shareholder value. The company remains committed to improving patient outcomes while addressing the growing challenges of prescription drug abuse.
For more details and the latest updates, visit Collegium Pharmaceutical's website.
Collegium Pharmaceutical (Nasdaq: COLL) announced a $25 million Accelerated Share Repurchase (ASR) agreement with Jefferies LLC, part of a larger $100 million share buyback program authorized in August 2021. Upon completion of this ASR, Collegium will have approximately $52.2 million remaining under the buyback authorization. The ASR involves repurchasing around 1,026,694 shares at the $19.48 closing stock price as of November 12, 2021. This move reflects management's confidence in the business and commitment to enhancing shareholder value.
Collegium Pharmaceutical, a leader in responsible pain management, announced its participation in upcoming investor conferences. Management will attend the Jefferies London Healthcare Conference with virtual one-on-one meetings on November 18, 2021, and the Piper Sandler Annual Healthcare Conference featuring a virtual fireside chat on December 1, 2021. The fireside chat will be accessible via the Investor section of their website, with a replay available for 30 days post-event. For more information, visit Collegium's website.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced its participation in two upcoming investor conferences. The Jefferies London Healthcare Conference will host virtual one-on-one meetings on November 18, 2021. Additionally, the Piper Sandler Annual Healthcare Conference 2021 will feature a virtual fireside chat on December 1, 2021. The fireside chat will be webcast, and a replay will be available on the company's Investor section website for 30 days following the event.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported a net income of $8.0 million and adjusted EBITDA of $37.3 million for Q3 2021. The company's Board has authorized a $25 million accelerated share repurchase, part of a broader $100 million initiative. Collegium aims for record full-year revenue and profits, driven by a strong pain management portfolio. Xtampza ER reached a 32.5% market share in ER oxycodone, while the Nucynta franchise exceeded $150 million in revenue. The company updated its 2021 financial guidance, adjusting Xtampza ER expected revenues down to $130-$135 million.
Collegium Pharmaceutical (Nasdaq: COLL) will host a conference call and live webcast on November 4, 2021, at 4:30 p.m. ET to discuss its Q3 2021 financial results and provide a corporate update. Investors can join the call by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers, referencing the "Collegium Pharmaceutical Q3 2021 Earnings Call." The webcast will be available on the company's website for replay shortly after the event.
Collegium Pharmaceutical (Nasdaq: COLL) presented four poster sessions at the Annual PAINWeek National Conference, emphasizing its commitment to responsible pain management.
The presentations focused on the misuse and abuse of its products, particularly XTAMPZA® ER and Nucynta®, and provided real-world data on their diversion and non-medical use.
These efforts highlight the company's dedication to scientific research and education among healthcare providers, reinforcing its position in the pain management sector.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced participation in two upcoming investor conferences in September 2021. The H.C. Wainwright 23rd Annual Global Investment Conference will feature a fireside chat on September 13, 2021, from 7:00 to 7:30 AM Eastern Time. Additionally, Collegium will present at the Cantor Virtual Global Healthcare Conference on September 28, 2021, from 8:00 to 8:30 AM Eastern Time. Both presentations will be accessible via the company's investor website, with replays available for 30 days post-event.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a $100 million share repurchase program, reflecting confidence in its growth and pain management portfolio. CEO Joe Ciaffoni emphasized their solid financial position and commitment to disciplined capital allocation. The program allows management flexibility in repurchasing shares based on market conditions and business needs, which could enhance shareholder value over time.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported strong financial results for Q2 2021, with net income of $72.8 million and adjusted EBITDA of $40.1 million. Xtampza® ER achieved a market share of 31.5% in the oxycodone extended-release market, marking a significant growth from 30.6% in March 2021. However, the company adjusted its revenue guidance downwards for Xtampza ER to $140.0-$150.0 million, while increasing guidance for the Nucynta Franchise to $195.0-$205.0 million. A conference call is scheduled for today at 4:30 p.m. ET to discuss these results further.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
What is Collegium Pharmaceutical, Inc.?
What is DETERx® technology?
What are the main products offered by Collegium?
What recent financial achievements has Collegium reported?
Where is Collegium Pharmaceutical headquartered?
How does Collegium's DETERx® technology help in preventing drug abuse?
What is Xtampza ER™?
How does Collegium Pharmaceutical return value to its shareholders?
What is the significance of Nucynta's regulatory exclusivity extension?
How can I stay updated on Collegium Pharmaceutical's latest news?
